Antibody titer 6 months after the third dose of COVID-19 mRNA vaccination

Abstract

Administration of the third dose of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine was initiated on December 1, 2021, in Japan. However, data on the long-term effects of this third vaccination remain scarce. Here, we examined the levels of SARS-CoV-2 antibodies in those who received the Pfizer BioNTech (BNT162b2) vaccine, 6 months after the third vaccination.

Keywords

• 6 months
• bnt162b2 vaccine
• duration
• humoral response
• sars-cov-2
• third vaccination